Treatment of epidermolysis bullosa pruriginosa using systemic and topical agents.
Department of Dermatology, Mayo Clinic, Phoenix, Arizona.
Aaron R
AR
Mangold
Department of Dermatology, Mayo Clinic, Phoenix, Arizona; Center for Dermatology Care, Thousand Oaks, California.
Christine M
CM
Cole
Department of Dermatology, Mayo Clinic, Phoenix, Arizona.
David J
DJ
DiCaudo
Department of Dermatology, Mayo Clinic, Phoenix, Arizona.
Mark R
MR
Pittelkow
Department of Dermatology, Mayo Clinic, Phoenix, Arizona. Electronic address: sekulic.aleksandar@mayo.edu.
Aleksandar
A
Sekulic
D000284:Administration, Oral; D000287:Administration, Topical; D000639:Amitriptyline / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004820:Epidermolysis Bullosa / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D016108:Epidermolysis Bullosa Dystrophica; D005260:Female; D005500:Follow-Up Studies; D005782:Gels; D006801:Humans; D007649:Ketamine / Q000627:therapeutic use; D035002:Lower Extremity; D008875:Middle Aged; D018570:Risk Assessment; D020280:Sertraline / Q000008:administration & dosage*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D005782:Gels; D000639:Amitriptyline; D007649:Ketamine; D020280:Sertraline